Alcon Laboratories, Inc.

---

The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® (travoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.

Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.

TRAVATAN Z® may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

---

Adults and children 3 years of age and older: Put 1 drop in the affected eye(s) twice daily, every 8-12 hours, no more than twice per day. Children under 3 years of age: Consult a doctor

---

Administer PATANASE Nasal Spray by the intranasal route only.

2.1 Adults and Adolescents 12 years of age and older:

The recommended dosage is two sprays per nostril twice daily.

2.2 Children 6 to 11 years of age:

The recommended dosage is one spray per nostril twice daily.

2.3 Administration Information

Priming: Before initial use, prime PATANASE Nasal Spray by releasing 5 sprays or until a fine mist appears. When PATANASE Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying PATANASE Nasal Spray into the eyes.

---

The recommended dose is 1 drop of AZOPT® (brinzolamide ophthalmic suspension) 1% in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.

---

Shake well before using. Instill 1 or 2 drops in the affected eye(s) as needed.

---

Pull down the lower lid of the affected eye and apply a small amount (one-fourth inch) of ointment to the inside of the eyelid.

---

Post-Operative Inflammation:

Apply one - two drops of VEXOL® 1% Ophthalmic Suspension into the conjunctival sac of the affected eye four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period.

Anterior Uveitis:

Apply one - two drops of VEXOL® 1% Ophthalmic Suspension into the conjunctival sac of the affected eye every hour during waking hours for the first week, one drop every two hours during waking hours of the second week, and then taper until uveitis is resolved.

---

Shake well before using. Instill 1 or 2 drops in the affected eye(s) as needed.

---

Vasoconstriction and Pupil Dilation: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% is especially useful when rapid and powerful dilation of the pupil without cycloplegia and reduction of congestion in the capillary bed are desired. A drop of a suitable topical anesthetic may be applied, followed in a few minutes by 1 drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% on the upper limbus. The anesthetic prevents stinging and consequent dilution of the solution by lacrimation. It may occasionally be necessary to repeat the instillation after one hour, again preceded by the use of the topical anesthetic.Uveitis: Posterior Synechiae: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used in patients with uveitis when synechiae are present or may develop. The formation of synechiae may be prevented by the use of this solution and atropine or other cycloplegics to produce wide dilation of the pupil. For recently formed posterior synechiae one drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be applied to the upper surface of the cornea and be repeated as necessary, not to exceed three times. Treatment may be continued the following day, if necessary. Atropine sulfate and the application of hot compresses should also be used if indicated.Glaucoma: MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be used with miotics in patients with open angle glaucoma. It reduces the difficulties experienced by the patient because of the small field produced by miosis, and still it permits and often supports the effect of the miotic in lowering the intraocular pressure in open angle glaucoma. Hence, there may be marked improvement in visual acuity after using MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% in conjunction with miotic drugs.Surgery: When a short-acting mydriatic is needed for wide dilation of the pupil before intraocular surgery, MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be applied topically from 30 to 60 minutes before the operation. Refraction: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used effectively to increase mydriasis with homatropine hydrobromide, cyclopentolate hydrochloride, tropicamide hydrochloride and atropine sulfate.FOR ADULTSOne drop of the preferred cycloplegic is placed in each eye, followed in 5 minutes by one drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5%. Since adequate cycloplegia is achieved at different time intervals after the instillation of the necessary number of drops, different cycloplegics will require different waiting periods to achieve adequate cycloplegia.FOR CHILDRENFor a “one application method,” MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be combined with one of the preferred rapid acting cycloplegics to produce adequate cycloplegia.Ophthalmoscopic Examination: One drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% is placed in each eye. Sufficient mydriasis to permit examination is produced in 15 to 30 minutes. Dilation lasts from one to three hours.Diagnostic Procedures: Provocative Test for Angle Closure Glaucoma: MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be used cautiously as a provocative test when interval narrow angle closure glaucoma is suspected. Intraocular tension and gonioscopy are performed prior to and after dilation of the pupil with phenylephrine HCl. A “significant” intraocular pressure (IOP) rise combined with gonioscopic evidence of angle closure indicates an anterior segment anatomy capable of angle closure. A negative test does not rule this out. This pharmacologically induced angle closure glaucoma may not simulate real life conditions and other causes for transient elevations of IOP should be excluded.Retinoscopy (Shadow Test): When dilation of the pupil without cycloplegic action is desired for retinoscopy, MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used.NOTE: Heavily pigmented irides may require larger doses in all of the above procedures.Blanching Test: One or two drops of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% should be applied to the injected eye. After five minutes, examine for perilimbal blanching. If blanching occurs, the congestion is superficial and probably does not indicate iridocyclitis.

---

One drop topically in the eye(s) as needed. May be used during ocular surgery. Do not use intracamerally. Discard unused portion.

---

Instill two drops topically in the eye(s) up to three times daily or as indicated by physician.

---

For refraction, administer one or two drops in the eye(s) one hour before refracting. For uveitis, administer one or two drops in the eye(s) up to four times daily.

---

For refraction, instill one or two drops topically in the eye(s). May be repeated in five to ten minutes if necessary. For uveitis, instill one or two drops topically up to every three to four hours. Individuals with heavily pigmented irides may require larger doses. Only the 2% strength should be used in pediatric patients.

---

Adults: For uveitis, administer one or two drops topically to the eye(s) up to four times daily.The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. Heavily pigmented irides may require larger doses.

---

2.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension

One drop of Isopto® Carpine 1%, 2% or 4% should be applied topically in the eye(s) up to four times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of Isopto® Carpine are determined by the severity of the elevated intraocular pressure and miotic response of the patient.To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of Isopto® Carpine ophthalmic solution.

2.2 Management of Acute Angle-Closure Glaucoma

Prior to Isopto® Carpine use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia. For initial management of acute angle-closure glaucoma, one drop of Isopto® Carpine 1% or 2% may be applied topically in the eye(s) up to three times over a 30-minute period.If laser iridoplasty or iridomy is used to break the attack, one drop of Isopto® Carpine 4% should be administered prior to the procedure. Following laser iridoplasty, one drop of Isopto® Carpine 1% should be administered four times daily until an iridotomy can be performed.

2.3 Prevention of Postoperative Elevated IOP Associated with Laser Surgery

One drop of Isopto® Carpine 1%, 2% or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s) 15 to 60 minutes prior to surgery.

2.4 Induction of Miosis

One drop of Isopto® Carpine 1%, 2% or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s).

2.5 Use with Other Topical Ophthalmic Medications

Isopto® Carpine may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

2.6 Use in Pediatric Patients

In children under 2 years of age, one drop of Isopto® Carpine 1% should be applied topically in the eye(s) three times daily. Children 2 years of age and over should be dosed as for adults. For the induction of miosis prior to goniotomy or trabeculotomy in children, one drop of Isopto® Carpine 1% or 2% should be applied topically in the eye 15 to 60 minutes prior to surgery.

---

Directions

Instill 1 or 2 drops in the affected eye(s) as needed.

---

In mild to moderate disease, instill one or two drops into the affected eye(s) every four hours. In severe infections, instill two drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

---

One or two drops instilled into the conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to one or two drops every two (2) hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.

Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

---

Instill one or two drops in the affected eye(s) as needed.

---

Put 1 or 2 drops in the affected eye(s) as needed.

---

Adults and children 3 years of age and older: Put 1 drop in the affected eye(s) twice daily, every 8-12 hours, no more than twice per day. Children under 3 years of age: Consult a doctor

---

Instill 1 or 2 drops in the affected eye(s) as needed.

---

adults and children 6 years and over: put 1 or 2 drops in the affected eye(s) up to 4 times daily children under 6 years: ask a doctor

---

Instill one or two drops in the affected eye(s) as needed.

---

2.1 Ocular Surgery

Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.

2.2 Endogenous Anterior Uveitis

Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.

---

Adults: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary. Small Infants: A single instillation of one drop of 0.5% in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation. Individuals with heavily pigmented irides may require higher strengths.

---

Instill 1 drop in the affected eye(s) 2 times daily for 7 days.

---

The recommended dosage of PAZEO is to instill one drop in each affected eye once a day.

---

The solution should be used according to the standard technique employed by the operating surgeon. For non-active irrigating system, use an administration set with an air-inlet in the plastic spike since the bag does not contain a separate airway tube. Follow the directions for the particular administration set to be used. Insert the spike aseptically into the bag through the center target area of the rubber stopper. Allow the fluid to flow to remove air from the tubing before intraocular irrigation begins.

---

The recommended dosage is one drop in the affected eye(s) once daily in the evening. IZBA (travoprost ophthalmic solution) 0.003% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. Reduction of the intraocular pressure starts approximately 2 hours after the first administration with maximum effect reached after 12 hours. IZBA may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

---

2.1 Recommended Dosing

One drop of ILEVRO* (nepafenac ophthalmic suspension), 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

2.2 Use with Other Topical Ophthalmic Medications

ILEVRO* (nepafenac ophthalmic suspension), 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

---

Apply a small amount (approximately 1/2 inch ribbon) into the conjunctival sac(s) up to three or four times daily.

How to apply TOBRADEX®(tobramycin and dexamethasone ophthalmic ointment) :

1. Tilt your head back.

2. Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid.

3. Place a small amount (about 1/2 inch) of TOBRADEX®(tobramycin and dexamethasone ophthalmic ointment) in the "V" pocket. Do not let the tip of the tube touch your eye.

4. Look downward before closing your eye.

Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

---

Directions

instill 1 or 2 drops in the affected eye(s) as needed.

---

Directions Flush the affected eye as needed, controlling the rate of flow of solution by pressure on the bottle.

---

Vasoconstriction and Pupil Dilation: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% is especially useful when rapid and powerful dilation of the pupil without cycloplegia and reduction of congestion in the capillary bed are desired. A drop of a suitable topical anesthetic may be applied, followed in a few minutes by 1 drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% on the upper limbus. The anesthetic prevents stinging and consequent dilution of the solution by lacrimation. It may occasionally be necessary to repeat the instillation after one hour, again preceded by the use of the topical anesthetic.Uveitis: Posterior Synechiae: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used in patients with uveitis when synechiae are present or may develop. The formation of synechiae may be prevented by the use of this solution and atropine or other cycloplegics to produce wide dilation of the pupil. For recently formed posterior synechiae one drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be applied to the upper surface of the cornea and be repeated as necessary, not to exceed three times. Treatment may be continued the following day, if necessary. Atropine sulfate and the application of hot compresses should also be used if indicated.Glaucoma: MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be used with miotics in patients with open angle glaucoma. It reduces the difficulties experienced by the patient because of the small field produced by miosis, and still it permits and often supports the effect of the miotic in lowering the intraocular pressure in open angle glaucoma. Hence, there may be marked improvement in visual acuity after using MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% in conjunction with miotic drugs.Surgery: When a short-acting mydriatic is needed for wide dilation of the pupil before intraocular surgery, MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be applied topically from 30 to 60 minutes before the operation. Refraction: MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used effectively to increase mydriasis with homatropine hydrobromide, cyclopentolate hydrochloride, tropicamide hydrochloride and atropine sulfate.FOR ADULTSOne drop of the preferred cycloplegic is placed in each eye, followed in 5 minutes by one drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5%. Since adequate cycloplegia is achieved at different time intervals after the instillation of the necessary number of drops, different cycloplegics will require different waiting periods to achieve adequate cycloplegia.FOR CHILDRENFor a “one application method,” MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be combined with one of the preferred rapid acting cycloplegics to produce adequate cycloplegia.Ophthalmoscopic Examination: One drop of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% is placed in each eye. Sufficient mydriasis to permit examination is produced in 15 to 30 minutes. Dilation lasts from one to three hours.Diagnostic Procedures: Provocative Test for Angle Closure Glaucoma: MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% may be used cautiously as a provocative test when interval narrow angle closure glaucoma is suspected. Intraocular tension and gonioscopy are performed prior to and after dilation of the pupil with phenylephrine HCl. A “significant” intraocular pressure (IOP) rise combined with gonioscopic evidence of angle closure indicates an anterior segment anatomy capable of angle closure. A negative test does not rule this out. This pharmacologically induced angle closure glaucoma may not simulate real life conditions and other causes for transient elevations of IOP should be excluded.Retinoscopy (Shadow Test): When dilation of the pupil without cycloplegic action is desired for retinoscopy, MYDFRIN® phenylephrine hydrochloride ophthalmic solution 2.5% may be used.NOTE: Heavily pigmented irides may require larger doses in all of the above procedures.Blanching Test: One or two drops of MYDFRIN phenylephrine hydrochloride ophthalmic solution 2.5% should be applied to the injected eye. After five minutes, examine for perilimbal blanching. If blanching occurs, the congestion is superficial and probably does not indicate iridocyclitis.